Effects of Beta-blockade on Platelet Aggregation in Acute Coronary Syndrome (PLATE-BLOCK)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02809820|
Recruitment Status : Unknown
Verified June 2016 by Giovanni Esposito, Federico II University.
Recruitment status was: Recruiting
First Posted : June 22, 2016
Last Update Posted : September 13, 2016
|Condition or disease||Intervention/treatment||Phase|
|Acute Coronary Syndrome||Drug: Carvedilol Drug: Metoprolol||Phase 4|
In patients with acute coronary syndrome (ACS) beta-blockers are recommended for secondary prevention. It is known that catecholamine levels can potentiate platelet reactivity and beta-blocking agents may also affect platelet aggregation. This effect is mainly mediated by adrenergic receptors on platelets. This suggests that nonselective beta-blockers would have a more pronounced effect on platelet aggregation than selective beta-blockers. However, little is known about the effect of beta-blockers on platelet aggregation in patients with cardiovascular disease and, to date, nothing is known in the setting of ACS.
The aim of the present study is to evaluate the effect of selective and nonselective beta-blockers on platelet aggregation in ACS patients treated with dual anti platelet therapy.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Effects of Selective and Nonselective Beta-blockade on Platelet Aggregation in Patients With Acute Coronary Syndrome|
|Study Start Date :||May 2016|
|Estimated Primary Completion Date :||November 2016|
|Estimated Study Completion Date :||December 2016|
Active Comparator: Carvedilol
Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume carvedilol.
Patients randomized to this group will receive carvedilol at the highest dose tolerated
Other Name: Selective beta-blocker
Active Comparator: Metoprolol
Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume metoprolol.
Patients randomized to this group will receive metoprolol at the highest dose tolerated
Other Name: Non Selective beta-blocker
- Platelet aggregation [ Time Frame: 30 days ]Platelet aggregation induced by epinephrine is measured by Light Transmission Aggregometry (LTA)
- 30-days platelet aggregation [ Time Frame: 30 days ]Platelet aggregation induced by Adenosine Diphosphate (ADP) is measured by Light Transmission Aggregometry (LTA)
- 30-days clinical events [ Time Frame: 30 days ]Major adverse cardiac events (MACE) and bleedings will be evaluated
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02809820
|Contact: Giovanni Esposito, MD PhD||0817463075 ext email@example.com|
|Contact: Federica Ilardi, MD||0817462240 ext firstname.lastname@example.org|
|Federico II University of Naples||Recruiting|
|Naples, Italy, 80131|
|Contact: Giovanni Esposito, MD PhD 0817463075 ext 0039 email@example.com|
|Principal Investigator: Giovanni Esposito, MD PhD|
|Principal Investigator:||Giovanni Esposito, MD PhD||Federico II University|